Combination PD-1/CTLA-4 inhibition has proven effective in several tumor types, improving on responses to single-agent ICB-therapy, and is now standard of care in malignant melanoma27 and renal cell carcinoma28. The gene discussed is PDCD1; the disease is neoplasm.